Literature DB >> 26202511

The reduction rate of serum C3 following liver transplantation is an effective predictor of non-anastomotic strictures.

Shuang Liu1, Tonghai Xing2, Tao Sheng2, Shouwen Yang2, Li Huang2, Zhihai Peng3, Xing Sun4.   

Abstract

PURPOSE: Non-anastomotic biliary strictures (NAS) are considered to be the thorniest complications following liver transplantation (LT). How to predict and adopt specific measures early to minimize the occurrence of it remains unclear. In this study, we aimed to find the relationship between the change rate of serum complement level and NAS.
METHODS: In a series of 232 adult patients who underwent their first LT, serum C3 and C4 concentrations at predetermined time points were collected. The correlation between the change rate of serum complement level following LT and the clinical outcome of NAS was retrospectively studied.
RESULTS: The reduction rate of serum C3 at the 1st day following LT in NAS patients was significantly different from that in non-NAS patients (p < 0.01). Receiver operating characteristic curve analysis demonstrated that the reduction rate of serum C3 is an effective predictor of NAS with an area under curve of 82.5 % (95 % CI 77.0-87.2 %). The reduction rate of C3 in the severe NAS group was significantly higher than that in the mild NAS group and the non-NAS group (p < 0.01).
CONCLUSIONS: Complement activation plays important roles on the progression of NAS. The reduction rate of serum C3 is an effective predictor of NAS.

Entities:  

Keywords:  Biliary complications; Complement activation; Liver transplantation; Non-anastomotic strictures

Year:  2014        PMID: 26202511     DOI: 10.1007/s12072-014-9524-x

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  37 in total

1.  Diffuse biliary tract injury after orthotopic liver transplantation.

Authors:  S Li; R J Stratta; A N Langnas; R P Wood; W Marujo; B W Shaw
Journal:  Am J Surg       Date:  1992-11       Impact factor: 2.565

Review 2.  The central role of the alternative complement pathway in human disease.

Authors:  Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

3.  Complement activation after ischemia-reperfusion in human liver allografts: incidence and pathophysiological relevance.

Authors:  J Y Scoazec; G Borghi-Scoazec; F Durand; J Bernuau; B N Pham; J Belghiti; G Feldmann; C Degott
Journal:  Gastroenterology       Date:  1997-03       Impact factor: 22.682

4.  Orthotopic homotransplantation of the human liver.

Authors:  T E Starzl; C G Groth; L Brettschneider; I Penn; V A Fulginiti; J B Moon; H Blanchard; A J Martin; K A Porter
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

5.  Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation.

Authors:  Carl Atkinson; Songqing He; Keeley Morris; Fei Qiao; Sarah Casey; Martin Goddard; Stephen Tomlinson
Journal:  J Immunol       Date:  2010-10-20       Impact factor: 5.422

6.  Complement alternative pathway acts as a positive feedback amplification of neutrophil activation.

Authors:  Laurent Camous; Lubka Roumenina; Sylvain Bigot; Soumeya Brachemi; Véronique Frémeaux-Bacchi; Philippe Lesavre; Lise Halbwachs-Mecarelli
Journal:  Blood       Date:  2010-11-09       Impact factor: 22.113

7.  Management of biliary tract complications after orthotopic liver transplantation.

Authors:  Sanjeet Thethy; Benjamin Nj Thomson; Henry Pleass; Stephen J Wigmore; Krishnakumar Madhavan; Murat Akyol; John Lr Forsythe; O James Garden
Journal:  Clin Transplant       Date:  2004-12       Impact factor: 2.863

8.  A simple modification in operative technique can reduce the incidence of nonanastomotic biliary strictures after orthotopic liver transplantation.

Authors:  H N Sankary; L McChesney; E Frye; S Cohn; P Foster; J Williams
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

Review 9.  Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies.

Authors:  Gwendolyn M P Diepenhorst; Thomas M van Gulik; C Erik Hack
Journal:  Ann Surg       Date:  2009-06       Impact factor: 12.969

10.  A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.

Authors:  Yuxiang Huang; Fei Qiao; Carl Atkinson; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.